Biblio
“BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.”, Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
, “Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
, “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.”, BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.
, “Fertility preservation: A key survivorship issue for young women with cancer ”, Frontiers in Oncology , vol. 6, no. 102, 2016.
, “Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.”, Gynecol Oncol, vol. 140, no. 1, p. 94, 2016.
, “Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention ”, Frontiers in Oncology , vol. 6, no. 00119 , 2016.
, “Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.”, J Gynecol Oncol, vol. 27, no. 3, p. e29, 2016.
, “Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.”, Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.
, “Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.”, Support Care Cancer, vol. 24, no. 3, p. 1249, 2016.
, “Reducing overtreatment in gynecologic oncology: the case for less in endometrial and ovarian cancer”, Frontiers in Oncology , vol. 6, no. 00118 , 2016.
, “Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet Oncol, vol. 17, no. 1, p. 89, 2016.
, “Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.”, N Engl J Med, vol. 374, no. 8, p. 748, 2016.
, ,
“Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.”, J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
, “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).”, Lancet Oncol, vol. 16, no. 3, pp. 301-11, 2015.
, “Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.”, Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
, “The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup.”, Int J Radiat Oncol Biol Phys, vol. 92, no. 3, pp. 506-8, 2015.
, “Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.”, Target Oncol, vol. 10, no. 4, pp. 583-96, 2015.
, “Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.”, Reprod Sci, vol. 22, no. 12, pp. 1509-15, 2015.
, “Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.”, Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
, “Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.”, Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
, “Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.”, Lancet Oncol, vol. 16, no. 8, p. 936, 2015.
, “Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: Results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study”, Ann Oncol, vol. 25, pp. 1320-7, 2014.
, “Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.”, J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
, “Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial”, Lancet Oncol, vol. 15, pp. 396-405, 2014.
,